Telisotuzumab vedotin (Teliso-V), an anti-c-Met-directed antibody-drug conjugate, was administered once every 2 or 3 weeks in recent phase I and phase II clinical trials in patients affected by NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.